1
|
Sieńko J, Kotowski M, Paczkowska E, Sobuś A, Tejchman K, Piątek J, Pilichowska E, Kędzierska-Kapuza K, Ostrowski M. Correlation Between Stem and Progenitor Cells Number and Immune Response in Patients After Allogeneic Kidney Transplant. Ann Transplant 2018; 23:874-878. [PMID: 30573723 PMCID: PMC6319141 DOI: 10.12659/aot.912686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Background Stem and progenitor cells are of great interest in all medical procedures involving tissue regeneration. There is a consensus that the use of stem cells after solid organ transplantation may play a role in tissue repair and in immunosuppression. The aim of this study was to determine possible relations between stem cell count and the immune response in a group of patients after kidney transplantation. Material/Methods The study was conducted on a group of 100 patients who underwent kidney transplantation. The following phenotypic markers of the studied cell subpopulations were adopted: Treg cells (CD3+CD4+CD25high), circulating hematopoietic cells (CD34+CD133+CD45+CD38−), and non-hematopoietic cells (Lin−CXCR4+CD133−CD45−). Cell subpopulations were assessed using LSRII flow cytometer (BD Biosciences, San Jose, CA, USA). Results Positive correlation was observed between non-hematopoietic stem cells percentage and recipient’s platelets count (P=0.04). Moreover, a higher percentage of non-hematopoietic cells was accompanied by lower numbers of B lymphocytes (P=0.03) and Treg cells (P=0.02). Conclusions Our study revealed significant associations between the intensity of ongoing immune response processes and tissue damage, and the release of stem and progenitor cells into circulation. These findings suggest their role in the stimulation of protective processes in terms of graft regeneration.
Collapse
Affiliation(s)
- Jerzy Sieńko
- Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland
| | - Maciej Kotowski
- Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland.,Department of General Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Edyta Paczkowska
- Department of General Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Anna Sobuś
- Department of General Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Karol Tejchman
- Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland
| | - Jarosław Piątek
- Department of Forensic Medicine, Pomeranian Medical University, Szczecin, Poland
| | - Ewa Pilichowska
- Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland
| | - Karolina Kędzierska-Kapuza
- Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland
| | - Marek Ostrowski
- Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland
| |
Collapse
|
2
|
Nouël A, Simon Q, Jamin C, Pers JO, Hillion S. Regulatory B cells: an exciting target for future therapeutics in transplantation. Front Immunol 2014; 5:11. [PMID: 24478776 PMCID: PMC3897876 DOI: 10.3389/fimmu.2014.00011] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Accepted: 01/08/2014] [Indexed: 12/19/2022] Open
Abstract
Transplantation is the preferred treatment for most end-stage solid organ diseases. Despite potent immunosuppressive agents, chronic rejection remains a real problem in transplantation. For many years, the predominant immunological focus of research into transplant rejection has been T cells. The pillar of immunotherapy in clinical practice is T cell-directed, which efficiently prevents acute T cell-mediated allograft rejection. However, the root of late allograft failure is chronic rejection and the humoral arm of the immune response now emerges as an important factor in transplantation. Thus, the potential effects of Abs and B cell infiltrate on transplants have cast B cells as major actors in late graft rejection. Consequently, a number of recent drugs target either B cells or plasma cells. However, immunotherapies, such as the anti-CD20 B cell-depleting antibody, can generate deleterious effects on the transplant, likely due to the deletion of beneficial population. The positive contribution of regulatory B (Breg) cells or B10 cells has been reported in the case of transplantation, mainly in mice models and highlights the primordial role that some populations of B cells can play in graft tolerance. Yet, this regulatory aspect remains poorly characterized in clinical transplantation. Thus, total B cell depletion treatments should be avoided and novel approaches should be considered that manipulate the different B cell subsets. This article provides an overview of the current knowledge on the link between Breg cells and grafts, and reports a number of data advising Breg cells as a new target for future therapeutic approaches.
Collapse
Affiliation(s)
- Alexandre Nouël
- EA2216 "Immunologie, Pathologie et Immunothérapie", Université de Brest, Université Européenne de Bretagne, SFR ScinBios, LabEx IGO "Immunotherapy, Graft, Oncology" , Brest , France
| | - Quentin Simon
- EA2216 "Immunologie, Pathologie et Immunothérapie", Université de Brest, Université Européenne de Bretagne, SFR ScinBios, LabEx IGO "Immunotherapy, Graft, Oncology" , Brest , France
| | - Christophe Jamin
- EA2216 "Immunologie, Pathologie et Immunothérapie", Université de Brest, Université Européenne de Bretagne, SFR ScinBios, LabEx IGO "Immunotherapy, Graft, Oncology" , Brest , France ; Laboratoire d'immunologie, CHRU Morvan , Brest , France
| | - Jacques-Olivier Pers
- EA2216 "Immunologie, Pathologie et Immunothérapie", Université de Brest, Université Européenne de Bretagne, SFR ScinBios, LabEx IGO "Immunotherapy, Graft, Oncology" , Brest , France ; Laboratoire d'immunologie, CHRU Morvan , Brest , France
| | - Sophie Hillion
- EA2216 "Immunologie, Pathologie et Immunothérapie", Université de Brest, Université Européenne de Bretagne, SFR ScinBios, LabEx IGO "Immunotherapy, Graft, Oncology" , Brest , France ; Laboratoire d'immunologie, CHRU Morvan , Brest , France
| |
Collapse
|